Biotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B market

A tiny biotech with a unique platform is stepping into the global spotlight—and it could be one of the most overlooked antiviral opportunities in the market today.

NanoViricides, Inc. (NYSE: NNVC) is developing NV-387, a broad-spectrum antiviral drug currently in human trials for COVID-19, with promising preclinical activity against major viral threats including:

  • SARS-CoV-2
  • RSV
  • Influenza
  • Measles
  • And now: MPox (monkeypox)

With the World Health Organization extending the global emergency status of the MPox epidemic, NNVC’s announcement that it is moving forward with Phase II trials for NV-387 in Africa’s deadliest Mpox clade (Clade I) is perfectly timed—and investors are starting to notice.

Analysts from Zacks SCR and ProactiveInvestors see the company’s nanomedicine platform as a potential game-changer in the $3B respiratory viral market—and potentially far beyond.

What sets NNVC apart?

✅ A first-in-class nanomedicine that traps viruses before they infect cells
✅ Broad-spectrum activity, even against mutating viruses
✅ A differentiated approach that may rival the pharma giants
✅ Platform potential with multiple shots on goal—COVID-19, RSV, measles, Mpox, and more

The company’s recent ethics approval in the DRC to begin Phase II human trials for MPox treatment puts NNVC on the front line of a growing global health concern—one with multi-billion-dollar pandemic and bioterror preparedness implications.

This isn’t just about treating MPox. This is about building a global antiviral defense system—and NNVC’s technology could play a vital role.

With momentum building and a pipeline unlike anything else in the small-cap space, NanoViricides, Inc. (NYSE: NNVC) may be positioning itself for breakout success.

👉 Get the full breakdown on NanoViricides (NYSE: NNVC) and why investors are tuning in now.


 
 
 
 
 
 

Monday's Featured Article

Wall Street Has Left Intel for Dead—Here's Why You Shouldn't

Written by Jeffrey Neal Johnson. Published 8/8/2025.

Intel logo on Building

Key Points

  • Intel's foundry business is gaining significant credibility by securing major, multi-year commitments from top-tier industry leaders for its advanced technologies.
  • The company is launching a pragmatic and aggressive assault on the enterprise AI market with a competitively priced accelerator that is gaining early adoption.
  • A revitalized core business is now delivering critically acclaimed PC processors that lead in efficiency and on-device AI performance, driving a resurgence.

The market landscape seems rocky and challenging for investors, considering Intel Corporation (NASDAQ: INTC). The stock is trading near the low end of its 52-week range, with an analyst consensus rating of Reduce.

This widespread pessimism, fueled by past manufacturing delays and market share losses, has pushed the company’s valuation to a significant discount, with a price-to-book ratio (P/B) of approximately 0.80, suggesting the market values Intel at less than the stated worth of its physical assets.

This negative perception, however, is creating a classic contrarian opportunity. While the market focuses on Intel’s past struggles, it largely overlooks three mighty, forward-looking pillars of a turnaround already delivering tangible results. 

For long-term investors, the disconnect between Intel’s analyst community and the reality of Intel's progress may represent a compelling entry or accumulation point.

Pillar 1: The Foundry

Intel’s most ambitious long-term strategy, its foundry business, is rapidly moving from a theoretical plan to a commercial reality. Anchored by multi-billion-dollar support from the U.S. CHIPS Act, Intel Foundry is positioned as a strategic, onshore manufacturing partner in an increasingly complex geopolitical world.

More importantly, the business is now being validated by major industry leaders who are committing to use its most advanced technology, providing tangible proof that its roadmap is competitive.

Recent cornerstone commitments include:

  • A Hyperscale Leader: Microsoft (NASDAQ: MSFT) has signed a multi-year agreement to use Intel’s advanced 18A process for a future custom chip, a massive vote of confidence from one of the world's largest chip buyers.
  • An AI Ecosystem Leader: Memory giant SK hynix will partner with Intel to use its advanced packaging technology. This involves precisely stacking SK hynix's critical High Bandwidth Memory (HBM) directly with processors, a technique essential for high-performance artificial intelligence (AI) systems. This partnership inserts Intel directly into the broader AI supply chain.
  • A Fabless Design Leader: Broadcom (NASDAQ: AVGO), a premier designer of high-end chips, has also committed to using the 18A process for a custom AI accelerator and networking chip.

For investors, securing commitments from this caliber of industry leaders significantly de-risks the foundry execution story.

These are concrete business deals that powerfully validate Intel’s technology and demonstrate a clear path to the long-term, high-margin revenue that the market is currently discounting.

Pillar 2: The AI Challenge

While building its foundry for the future, Intel is simultaneously launching an aggressive and pragmatic assault on the lucrative AI accelerator market. The company is directly challenging NVIDIA's market dominance with its Gaudi 3 AI accelerator, built on a clear and compelling value proposition of elite performance at a competitive price.

With an 8-accelerator kit priced at approximately $125,000, Gaudi 3 is positioned as a powerful alternative for enterprise customers struggling with the high cost and limited supply of competing solutions.

This value-focused strategy is already gaining commercial traction. Reports of early adoption by major industrial and enterprise companies indicate that a viable market exists for a strong second-source supplier in AI hardware.

To support this push, Intel's venture arm, Intel Capital, has also launched a new $500 million fund to invest in AI software startups. This is a strategic long-term play to build out a software ecosystem around its hardware, encouraging development and fostering wider adoption.

For investors, this multi-pronged strategy establishes a credible beachhead in the enterprise AI market and creates a new, high-growth revenue stream.

Pillar 3: The Core Resurgence

While pursuing future growth engines, Intel is also successfully revitalizing its core, revenue-driving PC business. The recent official launch of laptops featuring the new Lunar Lake processors marks the first major product victory under the company's renewed focus on execution.

The consensus from independent reviewers has been overwhelmingly positive, highlighting two key breakthroughs that directly address past criticisms.

First, Lunar Lake delivers class-leading power efficiency, resulting in what many are calling "all-day battery life" in premium thin-and-light laptops. This success makes Intel highly competitive in the most profitable segment of the PC market. 

Second, the chip's powerful on-device Neural Processing Unit (NPU) for AI tasks establishes Intel's leadership in the emerging AI PC category. This market, driven by new AI-powered features in operating systems like Windows, is expected to fuel the next major computer upgrade cycle.

For investors, it is tangible proof that the company's design and engineering excellence have returned. This success can drive market share gains and a higher-margin product mix in what remains the company's largest revenue segment.

Seeing Value Where Others See History

The story around Intel has been heavily shaped by its recent difficulties. Still, a look ahead shows a company built on three strong pillars of growth: a foundry business proven by top-tier clients, an aggressive AI plan that is gaining commercial success, and a revitalized core product line that is again delivering highly praised products.

This mountain of real progress sharply contrasts with the company's current stock valuation.

The prevailing negative market sentiment is creating a significant disconnect between perception and reality.

For investors with a long-term time horizon, this gap between the company's demonstrated progress and Intel’s current stock price may represent a compelling opportunity to invest in a turnaround that is already well underway.


 
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.
 
This email content is a paid advertisement for Smallcaps Daily, a third-party advertiser of InsiderTrades.com and MarketBeat.
 
 
This message is a paid advertisement for NanoViricides, Inc. (NYSE American: NNVC) from Smallcaps Daily and Sideways Frequency. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $2,500. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Smallcaps Daily or Sideways Frequency. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Sideways Frequency' website for additional information about the relationship between Sideways Frequency and NanoViricides, Inc. (NYSE American: NNVC).
 
 
If you have questions or concerns about your account, feel free to contact MarketBeat's U.S. based support team at contact@marketbeat.com.
 
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
 
© 2006-2025 MarketBeat Media, LLC.
345 North Reid Place, Suite 620, Sioux Falls, S.D. 57103. U.S.A..
 
Link of the Day: The Coin That Could Define Trump's Crypto Presidency (From Weiss Ratings)

Subscribe to receive free email updates:

0 Response to "Biotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B market"

Post a Comment